BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li SJ, Perez-Chada LM, Merola JF. TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management. J Psoriasis Psoriatic Arthritis 2019;4:70-80. [PMID: 31093599 DOI: 10.1177/2475530318810851] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Xu Y, Zhang Z, He J, Chen Z. Immune Effects of Macrophages in Rheumatoid Arthritis: A Bibliometric Analysis From 2000 to 2021. Front Immunol 2022;13:903771. [DOI: 10.3389/fimmu.2022.903771] [Reference Citation Analysis]
2 Townsend CM, Lovegrove F, Khanna R, Wilson AS. Review article: paradoxical psoriasis as a consequence of tumour necrosis factor antagonists in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2022;55:1379-88. [PMID: 35312094 DOI: 10.1111/apt.16883] [Reference Citation Analysis]
3 Costache DO, Feroiu O, Ghilencea A, Georgescu M, Căruntu A, Căruntu C, Țiplica SG, Jinga M, Costache RS. Skin Inflammation Modulation via TNF-α, IL-17, and IL-12 Family Inhibitors Therapy and Cancer Control in Patients with Psoriasis. Int J Mol Sci 2022;23:5198. [PMID: 35563587 DOI: 10.3390/ijms23095198] [Reference Citation Analysis]
4 Antonatos C, Panoutsopoulou M, Georgakilas GK, Evangelou E, Vasilopoulos Y. Gene Expression Meta-Analysis of Potential Shared and Unique Pathways between Autoimmune Diseases under Anti-TNFα Therapy. Genes 2022;13:776. [DOI: 10.3390/genes13050776] [Reference Citation Analysis]
5 Pagani K, Lukac D, Bhukhan A, McGee JS. Cutaneous Manifestations of Inflammatory Bowel Disease: A Basic Overview. Am J Clin Dermatol 2022. [PMID: 35441942 DOI: 10.1007/s40257-022-00689-w] [Reference Citation Analysis]
6 Tian D, Lai Y. The relapse of psoriasis: what’s the veil of mystery? JID Innovations 2022. [DOI: 10.1016/j.xjidi.2022.100116] [Reference Citation Analysis]
7 Yanai H, Amir Barak H, Ollech JE, Avni Biron I, Goren I, Snir Y, Banai Eran H, Broitman Y, Aharoni Golan M, Didkovsky E, Amitay-Laish I, Ollech A, Hodak E, Dotan I, Pavlovsky L. Clinical approach to skin eruptions induced by anti-TNF agents among patients with inflammatory bowel diseases: insights from a multidisciplinary IBD-DERMA clinic. Therap Adv Gastroenterol 2021;14:17562848211053112. [PMID: 34777576 DOI: 10.1177/17562848211053112] [Reference Citation Analysis]
8 Yang M, Liu W, Deng Q, Liang Z, Wang Q. The incidence of psoriasis among smokers and/or former smokers inflammatory bowel diseases patients treated with tumor necrosis factor antagonist: A systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e27510. [PMID: 34678884 DOI: 10.1097/MD.0000000000027510] [Reference Citation Analysis]
9 Bujoreanu FC, Bezman L, Radaschin DS, Niculet E, Bobeica C, Craescu M, Nadasdy T, Jicman DS, Ardeleanu V, Nwabudike LC, Marinescu SA, Tatu AL. Nevi, biologics for psoriasis and the risk for skin cancer: A real concern? (Case presentation and short review). Exp Ther Med 2021;22:1354. [PMID: 34659500 DOI: 10.3892/etm.2021.10789] [Reference Citation Analysis]
10 Haller C, Cozzio A, von Kempis J, Rubbert-Roth A. Successful Treatment of Rituximab-Associated Palmoplantar Pustulosis With Apremilast in a Patient With Seropositive Rheumatoid Arthritis. J Clin Rheumatol 2021;27:e289-90. [PMID: 32453211 DOI: 10.1097/RHU.0000000000001415] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Liang HY, Chen Y, Wei X, Ma GG, Ding J, Lu C, Zhou RP, Hu W. Immunomodulatory functions of TRPM7 and its implications in autoimmune diseases. Immunology 2021. [PMID: 34558663 DOI: 10.1111/imm.13420] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Ghazawi FM, Mahmood F, Kircik L, Poulin Y, Bourcier M, Vender R, Wiseman MC, Lynde C, Litvinov IV. A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab. Front Med (Lausanne) 2021;8:702776. [PMID: 34447766 DOI: 10.3389/fmed.2021.702776] [Reference Citation Analysis]
13 Cyrenne BM, Parpia AS, Sibbald C. Paradoxical psoriasis in pediatric patients: A systematic review. Pediatr Dermatol 2021. [PMID: 34402108 DOI: 10.1111/pde.14712] [Reference Citation Analysis]
14 Furuta H, Kato S, Masago K, Hida T. Palmoplantar Pustulosis Caused by Immune-Checkpoint Inhibitors. Clin Lung Cancer 2021:S1525-7304(21)00086-3. [PMID: 34023207 DOI: 10.1016/j.cllc.2021.04.002] [Reference Citation Analysis]
15 Tada Y, Ono N, Koarada S. Immediate Effect of Baricitinib on Arthritis and Biological Disease-Modifying Antirheumatic Drug-Induced Psoriasis-Like Skin Lesions in Two Patients with Rheumatoid Arthritis. Case Rep Rheumatol 2021;2021:8876847. [PMID: 33628569 DOI: 10.1155/2021/8876847] [Reference Citation Analysis]
16 Murphy MJ, Cohen JM, Vesely MD, Damsky W. Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis. J Am Acad Dermatol 2020:S0190-9622(20)33154-6. [PMID: 33307146 DOI: 10.1016/j.jaad.2020.12.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 7.5] [Reference Citation Analysis]
17 Polat Ekinci A, Pehlivan G, Öztürk Sarı Ş, Bölük KN, Büyükbabani N. Development of clear cell acanthoma during adalimumab therapy: Is it a novel paradoxical cutaneous reaction? Dermatol Ther 2020;33:e14316. [PMID: 32951308 DOI: 10.1111/dth.14316] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Chao Y, Hutto J, Keshvani N, Makris UE. Adalimumab-associated psoriasiform rash in an African-American patient. BMJ Case Rep 2020;13:e236376. [PMID: 32958552 DOI: 10.1136/bcr-2020-236376] [Reference Citation Analysis]
19 Grželj J, Sollner Dolenc M. The role of xenobiotics in triggering psoriasis. Arch Toxicol 2020;94:3959-82. [PMID: 32833044 DOI: 10.1007/s00204-020-02870-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Blüml S. [Biologicals and small molecules for rheumatoid arthritis]. Z Rheumatol 2020;79:223-31. [PMID: 32179964 DOI: 10.1007/s00393-020-00766-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Tian M, Ticer T, Wang Q, Walker S, Pham A, Suh A, Busatto S, Davidovich I, Al-Kharboosh R, Lewis-Tuffin L, Ji B, Quinones-Hinojosa A, Talmon Y, Shapiro S, Rückert F, Wolfram J. Adipose-Derived Biogenic Nanoparticles for Suppression of Inflammation. Small 2020;16:e1904064. [PMID: 32067382 DOI: 10.1002/smll.201904064] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]